ABSTRACT
Haloperidol is an anti-psychotic used for the treatment of schizophrenia or Tourette disorder. Here we report, by studying three large administrative health insurance databases, that haloperidol use is associated with a reduced risk of developing rheumatoid arthritis. A meta-analysis revealed a 31% reduced hazard of incident rheumatoid arthritis among individuals with schizophrenia or Tourette disorder treated with haloperidol compared to those treated with other anti-psychotic drugs. These findings suggest a potential benefit of haloperidol in rheumatoid arthritis and provide a rationale for randomized controlled trials to provide causal insights.
Competing Interest Statement
Sutton has received research grants from Boehringer Ingelheim, Coherus BioSciences, EMD Serono, and Alexion Pharmaceuticals, all for projects unrelated to study. Werner and Ambati are named as inventors on matter-related patent applications filed by their university.
Funding Statement
Werner and Ambati disclose support from the University of Virginia Strategic Investment Fund (SIF 167). Yerramothu acknowledges support from NIH grant R01EY029799. Sutton, Magagnoli, and Cummings disclose support from NIH grant R01DA054992 and the South Carolina Center for Rural and Primary Healthcare for projects unrelated to this study. This paper represents original research conducted using data from the Department of Veterans Affairs. This material is the result of work supported with resources and the use of facilities at the Dorn Research Institute, Columbia VA Health Care System, Columbia, South Carolina. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the US Department of Veterans Affairs, nor does mention of trade names, commercial products or organizations imply endorsement by the US government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
PearlDiver Mariner and IBM Marketscan Research Databases contained de-identified data deemed exempt by the University of Virginia Institutional Review Board (IRB). Veterans Administration (VA) Health database data analysis was compliant with Department of Veterans Affairs requirements and received IRB and Research and Development Approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY STATEMENT
All data supporting the findings of this study are available within the paper. Analyses of the Veterans Health Administration Database were performed using data within the US Department of Veterans Affairs secure research environment, the VA Informatics and Computing Infrastructure (VINCI). The other health insurance datasets are subject to licensing agreements and privacy restrictions. Researchers interested in accessing aggregate and individual data are encouraged to make direct enquiries to the corresponding author and should note they may also need to approach PearlDiver and IBM MarketScan for access to data from these sources.
